Prothena Corp. Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.16%285.311.5%$876.46m
GILDGilead Sciences, Inc. 1.70%89.291.0%$695.99m
MRNAModerna, Inc. 2.87%184.150.0%$670.48m
REGNRegeneron Pharmaceuticals, Inc. 0.59%768.812.6%$502.61m
VRTXVertex Pharmaceuticals, Inc. 1.26%321.591.9%$479.07m
BIIBBiogen, Inc. -1.26%288.471.8%$402.68m
ILMNIllumina, Inc. 0.84%210.283.2%$227.84m
BMRNBioMarin Pharmaceutical, Inc. 0.73%104.454.2%$163.38m
BNTXBioNTech SE 4.90%170.590.0%$158.07m
AXSMAxsome Therapeutics, Inc. 1.09%79.011.6%$148.54m
SNSSSunesis Pharmaceuticals, Inc. -4.15%1.850.7%$129.32m
RXDXPrometheus Biosciences, Inc 18.72%113.741.4%$123.29m
MRTXMirati Therapeutics, Inc. -10.73%44.271.6%$91.13m
NVAXNovavax, Inc. 0.06%17.2375.3%$81.93m
HALOHalozyme Therapeutics, Inc. -0.30%57.5718.4%$81.79m

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.